TBPN Diet TBPN: October 16th, 2025
33 snips
Oct 17, 2025 Hosts delve into Google's AI-generated cancer hypothesis and its implications in the medical field. They debate the limitations of AI in biotechnological advancements and explore regulatory hurdles impacting innovation. The conversation shifts to geopolitics, touching on trade dynamics with India and Russia. Joe Lonsdale’s insights on finance boosting job creation spark interest, while a concerning investigation reveals lead contamination in protein supplements. They also critique AI’s impact on creative production and analyze the branding skirmishes between PayPal and Wise.
AI Snips
Chapters
Transcript
Episode notes
AI-Aided Discovery In Biology
- Google used a 27B model to generate a novel cancer-cell hypothesis that lab scientists validated in living cells.
- This shows AI can assist early-stage biological discovery without yet proving treatments in animals or humans.
Cell-Level Wins Are Proofs, Not Cures
- The Google result is an important milestone but limited: validation occurred in cells, not animals or humans.
- The episode frames the result as a meaningful proof-of-concept for AI in bio, not a cure-all.
Scaling Bio Breakthroughs Faces S-Curve Limits
- Translating one discovery into thousands depends on scale, regulation, and real-world constraints.
- Progress may follow an S-curve as practical limits and regulation slow exponential advances.